Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection

Transplantation

Volumn 82, Issue 3, 2006, Pages 398-405

  Potena, Luciano ^a,b   Holweg, Cecile T J ^a   Chin, Clifford ^a   Luikart, Helen ^a   Weisshaar, Dana ^c   Narasimhan, Balasubramanian ^d   Fearon, William F ^a   Lewis, David B ^a   Cooke, John P ^a   Mocarski, Edward S ^a   Valantine, Hannah A ^a,e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Building 1   (United States)

^d STANFORD UNIVERSITY   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute rejection; Cardiac allograft disease; Cytomegalovirus; Heart transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; CYTOMEGALOVIRUS HYPERIMMUNE GLOBULIN; DACLIZUMAB; GANCICLOVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERIMMUNE GLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTERY DIAMETER; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SEROLOGY;

CARDIOVASCULAR DISEASES; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MIDDLE AGED; MUROMEGALOVIRUS; RISK FACTORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33747118343     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000229039.87735.76     Document Type: Article

References (38)

1. Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000; 2(3): 112.
2. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. Herpes 2004; 11(3): 77.
3. Griffiths PD, Cope AV, Hassan-Walker AF, Emery VC. Diagnostic approaches to cytomegalovirus infection in bone marrow and organ transplantation. Transpl Infect Dis 1999; 1(3): 179.
4. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261(24): 3561.
5. Valantine HA. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 2004; 4(2): 169.
6. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100(1): 61.
7. Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001; 72(10): 1647.
8. Tikkanen JM, Kallio EA, Bruggeman CA, et al. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts. Am J Respir Crit Care Med 2001; 164(4): 672.
9. Westall GP, Michaelides A, Williams TJ, et al. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003; 75(12): 2064.
10. Merigan TC, Renlund DG, Keay S, et al.Acontrolled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326(18): 1182.
11. Fishman JA. Prevention of CMV infection in transplant patients. Transpl Infect Dis 1999; 1 Suppl 1: 35.
12. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4(4): 611.
13. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 342(9): 613.
14. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9(6): 587.
15. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333(10): 621.
16. Kapadia SR, Ziada KM, L'Allier PL, et al. Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging. J Heart Lung Transplant 2000; 19(2): 167.
17. Pethig K, Heublein B, Meliss RR, Haverich A. Volumetric remodeling of the proximal left coronary artery: early versus late after heart transplantation. J Am Coll Cardiol 1999; 34(1): 197.
18. Nakamura M, Nishikawa H, Mukai S, et al. Impact of coronary artery remodeling on clinical presentation of coronary artery disease: an intravascular ultrasound study. J Am Coll Cardiol 2001; 37(1): 63.
19. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. CID 2002; 34: 1094.
20. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355(9220): 2032.
21. Michaelides A, Liolios L, Glare EM, et al. Increased human cytomegalovirus (HCMV) DNA load in peripheral blood leukocytes after lung transplantation correlates with HCMV pneumonitis. Transplantation 2001; 72(1): 141.
22. Lao WC, Lee D, Burroughs AK, et al. Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation. J Med Virol 1997; 51(3): 152.
23. Cantarovich M, Giannetti N, Cecere R. Relationship between endomyocardial biopsy score and cyclosporine 2-h post-dose levels (C) in heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplant 2004; 18(2): 148.
24. Yamani MH, Yousufuddin M, Starling RC, et al. Does acute cellular rejection correlate with cardiac allograft vasculopathy? J Heart Lung Transplant 2004; 23(3): 272.
25. Pethig K, Heublein B, Haverich A. Vascular remodeling in cardiac allograft vasculopathy. Z Kardiol 2000; 89 Suppl 9: IX/36.
26. Potena L, Grigioni F, Ortolani P, et al. Relevance of cytomegalovirus infection and coronary artery remodeling in the first year after transplantation. Transplantation 2003; 75(6): 839.
27. Nett PC, Heisey DM, Fernandez LA, et al. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004; 78(7): 1036.
28. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338(24): 1741.
29. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340(19): 1462.
30. Reischig T, Jindra P, Mares J, et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 2005; 79(3): 317.
31. Borchers AT, Perez R, Kaysen G, et al. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol 1999; 7(2): 75.
32. Kloover JS, Soots AP, Krogerus LA, et al. Rat cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellular adhesion molecule-1 vascular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft. Transplantation 2000; 69(12): 2641.
33. Martelius TJ, Blok MJ, Inkinen KA, et al. Cytomegalovirus infection, viral DNA, and immediate early-1 gene expression in rejecting rat liver allografts. Transplantation 2001; 71(9): 1257.
34. Meier-Kriesche HU,Ojo AO, Hanson JA, et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70(7): 1098.
35. Valantine HA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma." Transplantation 2003; 76(6): 891.
36. Jordan SC, Quartel AV, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin, (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allografts recipients and potential mechanisms of action. Transplantation 1998; 66(6): 800.
37. Potena L, Frascaroli G, Grigioni F, et al. Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation 2004; 109(4): 532.
38. Speir E, Yu Z, Ferrans V, Huang E, Epstein S. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ Res 1998; 83: 210.